×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SVRA – savara, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SVRA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/28
08:20 am
svra
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
3/27
07:05 am
svra
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Medium
Report
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
3/26
04:45 pm
svra
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
Low
Report
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
3/26
04:29 pm
svra
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
Low
Report
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
3/26
04:05 pm
svra
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Low
Report
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
3/17
08:05 am
svra
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
Low
Report
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
3/6
08:45 am
svra
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
Medium
Report
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
3/6
08:05 am
svra
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Low
Report
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/1
07:00 am
svra
Form 4 Savara Inc For: Mar 31 Filed by: RAMSAY DAVID A
Medium
Report
Form 4 Savara Inc For: Mar 31 Filed by: RAMSAY DAVID A
3/31
06:10 am
svra
Form 8-K Savara Inc For: Mar 31
Medium
Report
Form 8-K Savara Inc For: Mar 31
3/27
05:41 pm
svra
Form SCHEDULE 13D/A Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P.
Medium
Report
Form SCHEDULE 13D/A Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P.
3/27
07:30 am
svra
Form 10-K Savara Inc For: Dec 31
Medium
Report
Form 10-K Savara Inc For: Dec 31
3/26
05:01 pm
svra
Form 8-K Savara Inc For: Mar 26
Medium
Report
Form 8-K Savara Inc For: Mar 26
3/21
04:59 pm
svra
Form 3 Savara Inc For: Mar 13 Filed by: McCabe Kathleen R.
Low
Report
Form 3 Savara Inc For: Mar 13 Filed by: McCabe Kathleen R.
2/14
04:36 pm
svra
Form 4 Savara Inc For: Feb 13 Filed by: Lutz Robert Matthew
Low
Report
Form 4 Savara Inc For: Feb 13 Filed by: Lutz Robert Matthew
2/14
02:33 pm
svra
Form SCHEDULE 13G Savara Inc Filed by: Vestal Point Capital, LP
Low
Report
Form SCHEDULE 13G Savara Inc Filed by: Vestal Point Capital, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/30
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
180.6%
11/15 Form 8-K Savara Inc For: Nov 15 21.1%
11/27 Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 18.9%
12/20 Form 8-K Savara Inc For: Dec 20 15.1%
6/28 Form 4 Savara Inc For: Jun 26 Filed by: RAMSAY DAVID A 13.9%
12/20 Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million 10.4%
3/25 Statement Of Support By The PAP Foundation, Inc. For FDA Approval Of GM-CSF Treatment For aPAP 8.2%
10/31 Savara to Report Third Quarter 2019 Financial Results and Provide Business Update 7.3%
3/17 Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 6.3%
4/9 Form SC 13G/A Savara Inc Filed by: BlackRock Inc. 6.1%
11/15 Form 8-K Savara Inc For: Nov 15 21.1%
11/27 Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 18.9%
12/20 Form 8-K Savara Inc For: Dec 20 15.1%
6/28 Form 4 Savara Inc For: Jun 26 Filed by: RAMSAY DAVID A 13.9%
12/20 Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million 10.4%
3/25 Statement Of Support By The PAP Foundation, Inc. For FDA Approval Of GM-CSF Treatment For aPAP 8.2%
10/31 Savara to Report Third Quarter 2019 Financial Results and Provide Business Update 7.3%
3/17 Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 6.3%
4/9 Form SC 13G/A Savara Inc Filed by: BlackRock Inc. 6.1%
TOP News Decliners
10/2
Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
-58.5%
3/17 Form 4 Savara Inc For: Mar 10 Filed by: Sun Ricky -19.4%
2/3 Form 8-K Savara Inc For: Jan 31 -15.8%
4/2 Form 8-K Savara Inc For: Mar 31 -14.3%
12/30 Form SC 13D Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P. -12.8%
3/12 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus -0.310 ActVsEst (0.410) - Miss -9.8%
3/30 Savara Provides Business Update in Response to COVID-19 Pandemic -9.8%
12/3 Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors -8.4%
8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.430 ActVsEst (0.140) - Miss -8.4%
6/13 Savara Inc (NASDAQ: SVRA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.2%
3/17 Form 4 Savara Inc For: Mar 10 Filed by: Sun Ricky -19.4%
2/3 Form 8-K Savara Inc For: Jan 31 -15.8%
4/2 Form 8-K Savara Inc For: Mar 31 -14.3%
12/30 Form SC 13D Savara Inc Filed by: Bain Capital Life Sciences Fund II, L.P. -12.8%
3/12 Q4/2019 12/31/2019 EPS -0.720 ZacksConsensus -0.310 ActVsEst (0.410) - Miss -9.8%
3/30 Savara Provides Business Update in Response to COVID-19 Pandemic -9.8%
12/3 Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors -8.4%
8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.430 ActVsEst (0.140) - Miss -8.4%
6/13 Savara Inc (NASDAQ: SVRA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: